Month: July 2022

$RGGI Resgreen Group – PullBuddy™ AGV RGGI’s PullBuddy™ AGV will include a new brushless motor to increase horsepowerSHELBY TOWNSHIP, MI, July 20, 2022 (GLOBE NEWSWIRE) — Resgreen Group (OTC PINK: RGGI) (“RGGI”), a leading mobile robot company, today announced it is testing a new brushless motor for its robust PullBuddy™ Automatic Guided Vehicle (AGV), which moves loads up to 3,000 pounds. The brushless motor has a higher torque compared to the currently used brushed motor, which will lead to better performance and increased horsepower. In addition, the new motor requires less maintenance, resulting in a more robust unit. “Our engineering team is constantly looking for ways to improve our products, making them easier to manufacture, install and service for our customers,” said Parsh Patel, CEO at RGGI. “Our focus is finding...

LAS VEGAS, NV, July 20, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA), a Company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced that its wholly-owned subsidiary, HSTA HEALTH INC., purchased ten fully-automated HealthyYOU E-vending machines in connection with the Company’s vending pilot program. The technologically advanced, unattended HealthyYOU E-vending machines dispense healthy food, beverage, and wellness products to paying customers at the point of sale, accepting cash, coin, credit or debit cards, and payments by smartphones, watches and other devices. The Company’s goal is to create a technology-driven health and wellness...

MONTREAL, July 20, 2022 (GLOBE NEWSWIRE) — Mason Graphite Inc. (“Mason Graphite” or the “Company”) (TSX-V: LLG) (OTCQX: MGPHF) today announced the initial closing of the previously announced transactions contemplated under the investment agreement dated May 15, 2022 (the “Investment Agreement”) between the Company and Nouveau Monde Graphite Inc. (“Nouveau Monde”) (NYSE: NMG) (TSX-V: NOU). Pursuant to the Investment Agreement, Mason Graphite has entered into an option and joint venture agreement (the “OJV Agreement”) with Nouveau Monde. Concurrently with the execution of the OJV Agreement, Mason Graphite and Nouveau Monde have completed the private placement of 5.0 million common shares of the Company (the “Initial Shares”) to Nouveau Monde at a price of $0.50 per Inital Share for gross proceeds to the Company of $2.5 million. The...

Professor C.H.J. van Eijck, MD, PhD Professor C.H.J. van Eijck, MD, PhDAmpligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data provide further validation for advancing the development of Ampligen for the treatment of late-stage pancreatic cancer New data were recently presented by Professor C.H.J. van Eijck, MD, PhD of Erasmus Medical Center at the 5th Dutch Multidisciplinary Gastrointestinal Oncology Congress held in Ermelo, Netherlands OCALA, Fla., July 20, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune...

Överumans Fisk AB, a subsidiary of AS PRFoods, entered into loan agreements with Amber Trust II S.C.A., SICAR and Lindermann, Birnbaum & Kasela OÜ to borrow up to EUR 1,000,000 (up to EUR 500,000 from each lender). The repayment term of both loans is 31.12.2022 and the interest is 6.25% per annum. The new limit amount is EUR 1,705,000. The money is borrowed to support the start-up phase of Swedish fish farming and to boost company’s working capital at the same time. Fish will be farmed in Sweden’s largest and most environmentally friendly farm, using predominantly hydroelectric power or other renewable energy sources. The CO2 footprint of the fish farm is also about 1/3 smaller than, for example, in RAS-type i.e. terrestrial farms. The lenders are the shareholders of AS PRFoods and thus the related persons within the meaning...

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to enter clinical studiesREYKJAVIK, ICELAND (July 20, 2022) – Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®. The clinical study will assess the pharmacokinetics, safety and tolerability of AVT03 compared to Prolia® in healthy adult male subjects. Prolia® (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk of fracture. Xgeva® (denosumab),...

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to enter clinical studiesREYKJAVIK, Iceland, July 20, 2022 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®. The clinical study will assess the pharmacokinetics, safety and tolerability of AVT03 compared to Prolia® in healthy adult male subjects. Prolia® (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk of...